Aberdeen Group plc Sells 234,498 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Aberdeen Group plc cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 45.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 286,146 shares of the biotechnology company’s stock after selling 234,498 shares during the quarter. Aberdeen Group plc owned about 0.21% of Arrowhead Pharmaceuticals worth $18,997,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ARWR. Marex Group plc bought a new stake in Arrowhead Pharmaceuticals in the second quarter worth $576,000. Nordea Investment Management AB boosted its holdings in Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after acquiring an additional 158,937 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $2,823,000. Finally, Erste Asset Management GmbH lifted its holdings in shares of Arrowhead Pharmaceuticals by 55.3% during the third quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock valued at $2,466,000 after purchasing an additional 26,000 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total transaction of $641,900.00. Following the completion of the transaction, the insider directly owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ARWR has been the topic of a number of research analyst reports. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Chardan Capital upped their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. The Goldman Sachs Group upped their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Finally, Bank of America upped their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $61.12 on Tuesday. The stock has a market cap of $8.56 billion, a price-to-earnings ratio of 39.95 and a beta of 1.26. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The business has a 50-day simple moving average of $62.19 and a two-hundred day simple moving average of $55.12. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s revenue was up 10461.3% on a year-over-year basis. During the same period last year, the company earned ($1.39) EPS. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.